ASM Microbe 2026
June 4-7, 2026 – Washington, DC, USA
 ADLM 2026
July 26-30, 2026 – Anaheim, CA, USA
    1. Home
    2. Comp
    3. Anti-Comp monoclonal antibody

    Anti-Comp monoclonal antibody

    Mouse anti-Comp monoclonal antibody for WB, IHC, IP, ELISA

    Bring this labeled antibody directly to your bench!

    pdf COA pdf SDS pdf Datasheet
    Specifications
    Antibody Isotype
    IgG1
    Clone
    9I8
    Species Reactivity
    Rat
    Immunogen
    Recombinant protein corresponding to N-terminus region of rat Comp.
    Conjugate
    Unconjugated
    Applications
    Application Notes
    ELISA (1:500-1:1000); Immunoprecipitation (1:50-1:100); WB (1:100-1:300) & The optimal working dilution should be determined by the end user.
    Target
    Alternative Names
    COMP; cartilage oligomeric matrix protein;
    Entrez Gene ID
    25304
    UniProt ID
    P35444
    Product Background
    Pathway
    ECM-receptor interaction, organism-specific biosystem; ECM-receptor interaction, conserved biosystem; Focal adhesion, organism-specific biosystem; Focal adhesion, conserved biosystem; Malaria, organism-specific biosystem; Malaria, conserved biosystem; Phagosome, organism-specific biosystem;
    Custom Antibody Labeling
    We offer labeled antibodies using our catalogue antibody products and a broad range of intensely fluorescent dyes and labels including HRP, biotin, ALP, Alexa Fluor® dyes, DyLight® Fluor dyes, R-phycoerythrin (R-PE), at scales from less than 100 μg up to 1 g of IgG antibody. Learn More
    Citations Publication Publication (1)
    Have you cited DMABT-H12224 in a publication? Let us know and earn a reward for your research.

    MiR-29b-3p promotes chondrocyte apoptosis and facilitates the occurrence and development of osteoarthritis by targeting PGRN

    Lingqiang Chen, Qin Li, Jing Wang, Song Jin, Hongmei Zheng, Jun Lin, Fang He, Hong Zhang, Sha Ma, Jian Mei, Juan Yu
    J Cell Mol Med 2017 JunPubMed ID: 28609022Read Article
    Applications: WB
    Reactive species: Rat
    "Abstract: This study was aimed to explore the role of miR-29b-3p and PGRN in chondrocyte apoptosis and the initiation and progress of osteoarthritis (OA). Both miR-29b-3p and PGRN were up-regulated in cartilage tissue from patients with OA. Transfection of miR-29b-3p mimic into rat primary chondrocytes and SW1353 chondrosarcoma cells significantly suppressed PGRN expression and release, induced apoptosis, inhibited proliferation and scratch wound closure. By contrast, transfection of miR-29b-3p inhibitor exhibited the opposite effects. Moreover, the expression and secretion of cartilaginous degeneration-related molecules were also altered by miR-29b-3p. Luciferase reporter gene assay showed rat GRN mRNA is directly targeted and repressed by miR-29b-3p. The fact that recombinant PGRN or shPGRN-mediated PGRN interference abolished miR-29b-3p mimic-induced cell apoptosis and growth inhibition suggested miR-29b-3p affect the cellular functions of chondrocyte through regulating PGRN expression. In vivo, joint cavity injection of miR-29b-3p antagomir prior to surgical induction of OA significantly suppressed the upregulation of miR-29b-3p, whereas further promoted the increased expression of PGRN. Articular chondrocytes apoptosis and cartilage loss in the knee joint of surgically induced OA rats were also ameliorated by the injection of miR-29b-3p antagomir, demonstrated by TUNEL and safranin O-fast green staining. This work showed miR-29b-3p facilitates chondrocyte apoptosis and OA by targeting PGRN, and miR-29b-3p or PGRN may be the potential target for OA treatments."
    "Article snippet: The primary antibodies were as follows: Rabbit anti-human PGRN antibody (*), Rabbit anti-rat PGRN antibody (*), Rabbit anti-human Cleaved caspase-3 antibody (*), Rabbit anti-rat caspase-3 antibody (*), Anti-Bax antibody (*), Anti-Bcl-2 antibody (*), Anti-ADAMTS5 antibody (*), Anti-ADAMTS-7 antibody (*), Anti-MMP-1 antibody (*), Anti-MMP-13 antibody (*), Anti-COMP antibody (1:100, DMABT-H12224; Creative Diagnostics, Shirley, NY, USA), Anti-COL II antibody (*), Anti-Aggrecan antibody (*), Anti-COL X antibody (*), Anti-IL-1b antibody (*), Anti-TNF-a antibody (*), Anti-GAPDH antibody (*)."
    Protein levels of catabolic biomarkers (ADAMTS5, -7, MMP-1, -13 and COMP fragment), anabolic biomarkers (COL II and Aggrecan), the hypertrophic chondrocyte marker (COL X) and inflammatory cytokines (IL-1b and TNF-a). (Lingqiang Chen, <i>et al</i>, 2017)Figure 1. Protein levels of catabolic biomarkers (ADAMTS5, -7, MMP-1, -13 and COMP fragment), anabolic biomarkers (COL II and Aggrecan), the hypertrophic chondrocyte marker (COL X) and inflammatory cytokines (IL-1b and TNF-a).
    Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
    Customer Reviews

    Drug-Related Problems and Pharmacist Intervention at a General Hospital in the Jazan Region, Saudi Arabia

    RISK MANAGEMENT AND HEALTHCARE POLICY

    Authors: Babelghaith, Salmeen D.; Wajid, Syed; Alrabiah, Ziyad; Othiq, Mohammed Abdu M.; Alghadeer, Sultan; Alhossan, Abdulaziz; Al-Arifi, Mohamed; Attafi, Ibraheem M.

    Objective: This study examined the incidence of drug-related problems (DRPs) in different inpatient departments along with the medical team response to pharmacist's action in addressing DRPs at Jazan Hospital, Saudi Arabia. Patients and Methods: This retrospective study was conducted among inpatients at Ministry of Health hospital in Jazan, a region in southwestern Saudi Arabia. We collected data for a 2-year period (from 2016 to 2017). For any detected DRP of the ordered medications for dispensing, the inpatient pharmacist is sending report for that particular DRP with recommendation to the medical team which in turn might accept or reject such recommendation. Serious drug-drug interactions, as part of DRP, were assessed by utilizing three different online DDI checkers, including Lexi-Comp, Medscape, and Drugs.com . Results: The most common type of DRP was serious drug-drug interactions (49%). Over the study period, most incidences of DRPs were decreased. Of the DRPs in 2016 and 2017, antibiotics were the most commonly involved (51% and 69.5%) of cases, respectively, followed by proton pump inhibitors (25.3% and 14.1%) and statins (12.9% and 9.4%). Interestingly, of the 241 interventions for DRPs in 2016, 199 (82.5%) were accepted, resulting in a change in drug therapy (p=0.006). In 2017, 90 (70.3%) interventions out of 128 were accepted by the physician and the drug therapy changed (p=0.029). Conclusion: Pharmacist interventions appear to decrease the incidence of DRPs, which emphasize the importance of an optimal pharmaceutical care plan for clinical care settings.

    A Joint CoMP C-NOMA for Enhanced Cellular System Performance

    IEEE COMMUNICATIONS LETTERS

    Authors: Elhattab, Mohamed Kadry; Arfaoui, Mohamed Amine; Assi, Chadi

    The inter-cell interference (ICI) and the intra-user interference in non-orthogonal multiple access (NOMA) cellular networks have serious impacts on the performance of cell edge users. In this letter, we investigate the integration of coordinated multipoint (CoMP) transmission and cooperative NOMA (C-NOMA) aiming to improve the performance of cell edge users. Using this framework, we exploit the cooperation between base stations (BSs) to mitigate the ICI and the successive decoding of users that are near the BSs to further enhance the performance of cell edge users. In this setting, we derive a closed form expression for the outage probability of a cell edge user along with an analytical expression for its ergodic rate. We validate the derived expressions through various Monte-Carlo simulations, where we show the superiority of the proposed framework compared with other multiple access schemes proposed in the literature.
    Comp Related Products
    You may also be interested in
    Human COMP Antibody Pair Set (ABPR-ZB347)

    Human COMP Antibody Pair Set (ABPR-ZB347)

    Online Inquiry
    Catalog # DMABT-H12224

    Please Inquiry

    Request bulk or custom quote

      Save to Inquiry Basket
      Performance Guarantee
    Related Products
    By targets
    Ordering Information
    Payment methods we support:
    Invoice / Purchase Order
    Credit card

    Credit card

    Inquiry Basket